{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:27:42Z","timestamp":1790162862837,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","funder":[{"DOI":"10.13039\/501100003030","name":"AGAUR","doi-asserted-by":"publisher","award":["2014SGR26"],"award-info":[{"award-number":["2014SGR26"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"DOI":"10.1093\/jac\/dkx516","type":"journal-article","created":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T04:07:43Z","timestamp":1513570063000},"page":"1060-1067","source":"Crossref","is-referenced-by-count":72,"title":["What to expect and when: benznidazole toxicity in chronic Chagas\u2019 disease treatment"],"prefix":"10.1093","volume":"73","author":[{"given":"E","family":"Aldasoro","sequence":"first","affiliation":[{"name":"International Health Service, Hospital Clinic Barcelona, Barcelona, Spain"},{"name":"ISGlobal, Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Posada","sequence":"additional","affiliation":[{"name":"International Health Service, Hospital Clinic Barcelona, Barcelona, Spain"},{"name":"ISGlobal, Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Requena-M\u00e9ndez","sequence":"additional","affiliation":[{"name":"International Health Service, Hospital Clinic Barcelona, Barcelona, Spain"},{"name":"ISGlobal, Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Calvo-Cano","sequence":"additional","affiliation":[{"name":"International Health Service, Hospital Clinic Barcelona, Barcelona, Spain"},{"name":"ISGlobal, Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Serret","sequence":"additional","affiliation":[{"name":"International Health Service, Hospital Clinic Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Casellas","sequence":"additional","affiliation":[{"name":"ISGlobal, Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Sanz","sequence":"additional","affiliation":[{"name":"ISGlobal, Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Soy","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Hospital Clinic Barcelona, Barcelona, Spain"},{"name":"Institut de Investigaci\u00f3 Biom\u00e8dica Agust\u00ed Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"Pinazo","sequence":"additional","affiliation":[{"name":"International Health Service, Hospital Clinic Barcelona, Barcelona, Spain"},{"name":"ISGlobal, Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Gascon","sequence":"additional","affiliation":[{"name":"International Health Service, Hospital Clinic Barcelona, Barcelona, Spain"},{"name":"ISGlobal, Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,1,16]]},"reference":[{"key":"key\n\t\t\t\t20180316035320_dkx516-B1","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0140-6736(10)60061-X","article-title":"Chagas disease","volume":"375","author":"Rassi","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.medcli.2016.10.038","article-title":"Orally-transmitted Chagas disease","volume":"148","author":"Filigheddu","year":"2017","journal-title":"Med Clin (Barc)"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B3","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1086\/651608","article-title":"Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas, Venezuela","volume":"201","author":"Alarc\u00f3n de Noya","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B4","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(10)61372-4","article-title":"Antitrypanosomal agents: treatment or threat?","volume":"376","author":"Issa","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B5","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1001\/jama.298.18.2171","article-title":"Evaluation and treatment of Chagas disease in the United States: a systematic review","volume":"298","author":"Bern","year":"2007","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/B978-0-12-385863-4.00002-2","article-title":"Acute and congenital Chagas disease","volume":"75","author":"Bern","year":"2011","journal-title":"Adv Parasitol"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1590\/S0074-02762009000900041","article-title":"Ergosterol biosynthesis and drug development for Chagas disease","volume":"104","author":"Urbina","year":"2009","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B8","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1056\/NEJMoa1507574","article-title":"Randomized trial of benznidazole for chronic Chagas\u2019 cardiomyopathy","volume":"373","author":"Morillo","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B9","first-page":"189.","article-title":"Benznidazole for chronic Chagas\u2019 cardiomyopathy","volume":"374","author":"Urbina","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1128\/AAC.01662-13","article-title":"Towards a paradigm shift in the treatment of chronic Chagas disease","volume":"58","author":"Viotti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B11","doi-asserted-by":"crossref","first-page":"724","DOI":"10.7326\/0003-4819-144-10-200605160-00006","article-title":"Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial","volume":"144","author":"Viotti","year":"2006","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B12","first-page":"19","article-title":"Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas\u2019 disease)","volume":"1","author":"Castro","year":"1988","journal-title":"Biomed Environ Sci"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4269\/ajtmh.2012.12-0080","article-title":"Benznidazole shortage makes Chagas disease a neglected tropical disease in developed countries: data from Spain","volume":"87","author":"Navarro","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B14","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1128\/AAC.04660-14","article-title":"Toxic profile of benznidazole in patients with chronic Chagas disease: risk factors and comparison of the product from two different manufacturers","volume":"59","author":"Molina","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B15","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316856","volume-title":"Variance Components","author":"Searle","year":"1992"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B16","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/cid\/civ005","article-title":"Tolerance of benznidazole in a United States Chagas Disease clinic","volume":"60","author":"Miller","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B17","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1128\/AAC.00537-10","article-title":"Tolerance of benznidazole in treatment of Chagas\u2019 disease in adults","volume":"54","author":"Pinazo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B18","first-page":"123","article-title":"Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country","volume":"24","author":"Carrilero","year":"2011","journal-title":"Rev Esp Quimioter"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B19","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.1128\/AAC.02842-14","article-title":"A clinical adverse drug reaction prediction model for patients with Chagas disease treated with benznidazole","volume":"58","author":"Sperandio da Silva","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B20","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/cid\/civ230","article-title":"High frequency of adverse reactions and discontinuation with benznidazole treatment for chronic Chagas disease in Milan, Italy","volume":"60","author":"Antinori","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B21","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/bjd.14451","article-title":"Two cases of overlap severe cutaneous adverse reactions to benznidazole treatment for asymptomatic Chagas disease in a nonendemic country","volume":"175","author":"Gonz\u00e1lez-Ramos","year":"2016","journal-title":"Br J Dermatol"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B22","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaip.2014.08.003","article-title":"Acute generalized exanthematous pustulosis due to benznidazole","volume":"2","author":"\u00c1lava-Cruz","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1128\/AAC.04078-14","article-title":"Arthritis and benznidazole: more closely related than we thought","volume":"59","author":"Aldasoro","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1586\/14787210.7.2.157","article-title":"Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities","volume":"7","author":"Viotti","year":"2009","journal-title":"Expert Rev Anti Infect Ther"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1590\/S0036-46652002000100006","article-title":"Long term evaluation of etiological treatment of Chagas disease with benznidazole","volume":"44","author":"Cancado","year":"2002","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B26","doi-asserted-by":"crossref","first-page":"e2410.","DOI":"10.1371\/journal.pntd.0002410","article-title":"Socio-cultural aspects of Chagas disease: a systematic review of qualitative research","volume":"7","author":"Ventura-Garcia","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B27","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2471\/BLT.13.134072","article-title":"Economic crisis and increased immigrant mobility: new challenges in managing Chagas disease in Europe","volume":"92","author":"Jackson","year":"2014","journal-title":"Bull World Health Organ"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B28","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/cid\/civ690","article-title":"Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease","volume":"61","author":"Salvador","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B29","doi-asserted-by":"crossref","first-page":"e0004343.","DOI":"10.1371\/journal.pntd.0004343","article-title":"The BENEFIT trial: where do we go from here?","volume":"10","author":"Pecoul","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"key\n\t\t\t\t20180316035320_dkx516-B30","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1128\/AAC.05018-14","article-title":"Population pharmacokinetics of benznidazole in adult patients with Chagas disease","volume":"59","author":"Soy","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/4\/1060\/24269631\/dkx516.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T22:55:37Z","timestamp":1751151337000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/4\/1060\/4812656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,16]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,1,16]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx516","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4]]},"published":{"date-parts":[[2018,1,16]]}}}